Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024

Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi

Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years

Neuland Laboratories Q2 FY25 consolidated PAT falls to Rs. 32.84 Cr

Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024

Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

The company uses iPS cells to develop treatments for diseases relating to the kidney

Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece

Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr

Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024

Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr

Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

Revenue growth was fueled by higher volumes and contributions from both existing and new centres

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25